Distinct Immune Signatures in Peripheral Blood Predict Chemosensitivity in Intrahepatic Cholangiocarcinoma Patients

Abstract

Intrahepatic cholangiocarcinoma (ICC) is the second most common liver cancer. Chemotherapy remains the main therapeutic strategy for advanced ICC patients, but chemosensitivity varies individually. Here, we applied cytometry by time-of-flight (CyTOF) to establish the immune profile of peripheral blood mononuclear cells (PBMCs) on the single-cell level at indicated time points before, during, and after chemotherapy. Multiplex immunofluorescence staining was applied to examine the spatial distribution of certain immune clusters. Tissue microarrays (TMAs) were used for prognostic evaluation. A total of 20 ICC patients treated with gemcitabine (GEM) were enrolled in our study, including eight cases with good response (R) and 12 cases with non-response (NR). Tremendous changes in PBMC composition, including an increased level of CD4/CD8 double-positive T cells (DPT), were observed after chemotherapy. Patients with higher level of CD4⁺CD45RO⁺CXCR3⁺ T cells before treatment had a favorable response to chemotherapy. Our study identified a positive correlation between the percentage of T cell subpopulations and clinical response after chemotherapy, which suggests that it is practical to predict the potential response before treatment by evaluating the proportions of the cell population in PBMCs.

Keywords

Intrahepatic cholangiocarcinoma / Gemcitabine / Chemosensitivity / Peripheral blood mononuclear cells

References

[[1]] Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014;60(6):1268–89.

[[2]] Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248(1):84–96.

[[3]] El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2019;28(4):587–99.

[[4]] Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383(9935): 2168–79.

[[5]] Chew V, Lee YH, Pan Lu, Nasir NJM, Lim CJ, Chua C, et al. Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019;68(2):335–46.

[[6]] Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996;14(3):257–63.

[[7]] Nezami N, Camacho JC, Kokabi N, El-Rayes BF, Kim HS. Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin. J Gastrointest Oncol 2019;10(5):944–56.

[[8]] Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, et al. Secondline chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. Cancer 2019;125(24):4426–34.

[[9]] Xie X, Ma L, Zhou Y, Shen W, Xu D, Dou J, et al. Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-jB pathway in vitro/vivo. Carbohydr Polym 2019;225:115223.

[[10]] Mu XY, Wang RJ, Yao ZX, Zheng Z, Jiang JT, Tan MY, et al. RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment. Mol Immunol 2019;109:140–8.

[[11]] Zhang LN, Xin T, Chen M, Gao P. Chemoresistance in mesenchymal lung cancer cells is correlated to high regulatory T cell presence in the tumor microenvironment. IUBMB Life 2019;71(7):986–91.

[[12]] Duan S, Wang P, Liu F, Huang H, An W, Pan S, et al. Novel immune-risk score of gastric cancer: a molecular prediction model combining the value of immunerisk status and chemosensitivity. Cancer Med 2019;8(5):2675–85.

[[13]] Givechian KB, Wnuk K, Garner C, Benz S, Garban H, Rabizadeh S, et al. Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. NPJ Genom Med 2018;3(1):14.

[[14]] Zheng B, Wang D, Qiu X, Luo G, Wu T, Yang S, et al. Trajectory and functional analysis of PD-1(high) CD4+ CD8+ T cells in hepatocellular carcinoma by singlecell cytometry and transcriptome sequencing. Adv Sci 2020;7(13):2000224.

[[15]] Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 2018;3(8):e97828.

[[16]] Ouyang H, Zhang L, Xie Z, Ma S. Long noncoding RNA MAFG-AS1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852. Exp Ther Med 2019;18(4):2547–53.

[[17]] Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Lett 2019;458:123–35.

[[18]] Cao Z, Ji J, Zhang C, Wang F, Xu H, Yu Y, et al. The preoperative neutrophil-tolymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy. Cancer Med 2019;8(3):1004–12.

[[19]] Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, et al. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. J Immunother Cancer 2019;7(1):10.

[[20]] Kostine M, Briaire-de Bruijn IH, Cleven AHG, Vervat C, Corver WE, Schilham MW, et al. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. OncoImmunology 2018;7(2):e1386828.

[[21]] Krupar R, Hautmann MG, Pathak RR, Varier I, McLaren C, Gaag D, et al. Immunometabolic determinants of chemoradiotherapy response and survival in head and neck squamous cell carcinoma. Am J Pathol 2018;188(1):72–83.

[[22]] Ganesan P, Mehra N, Joel A, Radhakrishnan V, Dhanushkodi M, Perumal Kalayarasi J, et al. Gemcitabine, vinorelbine and dexamethasone: a safe and effective regimen for treatment of relapsed/refractory Hodgkin’s lymphoma. Leuk Res 2019;84:106188.

[[23]] Zeng FL, Xiao Z, Wang CQ, Jiang Y, Shan JL, Hu SS, et al. Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: a systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. Int Immunopharmacol 2019;75:105747.

[[24]] Tucci ST, Kheirolomoom A, Ingham ES, Mahakian LM, Tam SM, Foiret J, et al. Tumor-specific delivery of gemcitabine with activatable liposomes. J Control Release 2019;309:277–88.

[[25]] Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, et al. Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells. Eur Urol 2019;76(4):430–4.

[[26]] Kim JW, Lee KH, Kim JW, Suh KJ, Nam AR, Bang JH, et al. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. Br J Cancer 2019;121(4):332–9.

[[27]] Ahn KS, O’Brien D, Kang YN, Mounajjed T, Kim YH, Kim TS, et al. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecularclinical analysis and potential targeted approach. Hepatol Int 2019;13 (4):490–500.

[[28]] Schneible JD, Singhal A, Lilova RL, Hall CK, Grafmüller A, Menegatti S. Tailoring the chemical modification of chitosan hydrogels to fine tune the release of a synergistic combination of chemotherapeutics. Biomacromolecules 2019;20 (8):3126–41.

[[29]] Zhao P, Zhu D, Zhang Z, Han B, Gao D, Wei X, et al. Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4+ CD25bri regulatory T cells. Immunol Lett 2017;181:36–44.

[[30]] Li Z, Wang C, Deng H, Wu J, Huang H, Sun R, et al. Robust photodynamic therapy using 5-ALA-incorporated nanocomplexes cures metastatic melanoma through priming of CD4+ CD8+ double positive T cells. Adv Sci 2019;6 (5):1802057.

[[31]] Kim R, Kawai A, Wakisaka M, Funaoka Y, Yasuda N, Hidaka M, et al. A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients. Cancer Immunol Immunother 2019;68(4):577–85.

[[32]] Giraldo NA, Bolaños NI, Cuellar A, Guzman F, Uribe AM, Bedoya A, et al. Increased CD4+ /CD8+ double-positive T cells in chronic chagasic patients. PLoS Negl Trop Dis 2011;5:e1294.

[[33]] Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell 2018;23 (6):850–8.e4.

[[34]] Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014;32 (1):659–702.

[[35]] Chen YP, Wu HL, Boyé K, Pan CY, Chen YC, Pujol N, et al. Oligomerization state of CXCL4 chemokines regulates G protein-coupled receptor activation. ACS Chem Biol 2017;12(11):2767–78.

[[36]] Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996;184(3):963–9.

[[37]] Luster AD, Leder P. IP-10, a-CXC-chemokine, elicits a potent thymusdependent antitumor response in vivo. J Exp Med 1993;178(3):1057–65.

[[38]] Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004;64 (21):7697–701.

[[39]] Medler TR, Murugan D, Horton W, Kumar S, Cotechini T, Forsyth AM, et al. Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell 2018;34(4):561–78.e6.

[[40]] Thomas SN, Vokali E, Lund AW, Hubbell JA, Swartz MA. Targeting the tumordraining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 2014;35(2):814–24.

[[41]] Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler’s guide to cytometry. Trends Immunol 2012;33(7):323–32.

[[42]] Wu T, Wu X, Wang HY, Chen L. Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. Cancer Commun 2019;39(1):21.

[[43]] Landhuis E. Single-cell approaches to immune profiling. Nature 2018;557 (7706):595–7.

[[44]] Atkuri KR, Stevens JC, Neubert H. Mass cytometry: a highly multiplexed singlecell technology for advancing drug development. Drug Metab Dispos 2015;43 (2):227–33.